Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

Clinical trial NCT07387926 · RECRUITING

Trial details

NCT number: NCT07387926
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Lymphoblastic Leukemia Leukemia, Lymphoblastic, Acute, Philadelphia-Positive Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Start date: 2026-07-05
Primary completion: 2033-09-19
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.